Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma-Reference-Cited by-同舟云学术

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Published:2015-09-24 Issue:13 Volume:373 Page:1207-1219
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Lokhorst Henk M.,Plesner Torben,Laubach Jacob P.,Nahi Hareth,Gimsing Peter,Hansson Markus,Minnema Monique C.,Lassen Ulrik,Krejcik Jakub,Palumbo Antonio,van de Donk Niels W.C.J.,Ahmadi Tahamtan,Khan Imran,Uhlar Clarissa M.,Wang Jianping,Sasser A. Kate,Losic Nedjad,Lisby Steen,Basse Linda,Brun Nikolai,Richardson Paul G.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1506348

Cited by 957 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis;Hematology;2024-09-09

2. CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity;Molecular Therapy: Oncology;2024-09

3. Molecular Signatures of CB-6644 Inhibition of the RUVBL1/2 Complex in Multiple Myeloma;International Journal of Molecular Sciences;2024-08-20

4. The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease;Pharmaceuticals;2024-08-05

5. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial;The Lancet Oncology;2024-08